Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity
Open Access
- 11 September 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (18) , 19339-19376
Abstract
Mpro of SARS-CoV-2 plays a vital role in the replication and pathogenesis of virus. Additionally, its high conservation within the Coronaviridae family makes it an attractive therapeutic target for developing broad-spectrum agents. This study describes the design, synthesis, and structure-activity relationships of azapeptide-based SARS-CoV-2 Mpro inhibitors, leading to several compounds with nanomolar IC50 values. Examples include 14r (IC50 = 13.3 nM), 14s (IC50 = 30.6 nM), 20a (TPG-20a, IC50 = 28.0 nM), and 20g (IC50 = 30.4 nM). Some compounds inhibit MERS-CoV and SARS-CoV-1 Mpro but not the human protease cathepsin L. Several inhibitors, such as 20a and 20f, exhibit antiviral activity with potencies comparable to nirmatrelvir and activity against the E166V-carrying SARS-CoV-2 variant (SARS-CoV-2E166V). An Mpro cocrystal structure with 20a shows a covalent adduct with the catalytic Cys145. Overall, these new inhibitors are promising chemical tools that may contribute to the identification of future pan-anticoronaviral drugs.Keywords
All Related Versions
Funding Information
- Howard Hughes Medical Institute
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (200069/2024-1)
- University of Texas Health Science Center at San Antonio
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.911426/2023-00)
- Volkswagen Foundation
This publication has 79 references indexed in Scilit:
- Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitorsAntiviral Research, 2024
- Development of an active-site titrant for SARS-CoV-2 main protease as an indispensable tool for evaluating enzyme kineticsActa Pharmaceutica Sinica B, 2024
- Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main proteaseActa Pharmaceutica Sinica B, 2022
- Twin combination of Omicron and Delta variants triggering a tsunami wave of ever high surges in COVID‐19 cases: A challenging global threat with a special focus on the Indian subcontinentJournal of Medical Virology, 2022
- Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored InhibitorsAngewandte Chemie International Edition, 2021
- Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastorisBiotechnology Letters, 2012
- Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization modeProtein & Cell, 2010
- Azadipeptide Nitriles: Highly Potent and Proteolytically Stable Inhibitors of Papain‐Like Cysteine ProteasesAngewandte Chemie International Edition, 2008
- Novel Aza Peptide Inhibitors and Active‐Site Probes of Papain‐Family Cysteine ProteasesChemBioChem, 2006
- Characterization of SARS main protease and inhibitor assay using a fluorogenic substrateBiochemical and Biophysical Research Communications, 2004